ArticleScientific reports2025
Presence of high-risk nano particulate matters in powder injection: microscopic evaluation and investigation of particles contamination.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optical imaging and spectroscopic characterization of subvisible particles in protein therapeutics.Advanced drug delivery reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To analyse the health hazard particles in injection. By using different analytical techniques, we have found nanoparticles within injections. Complex parenteral products are prone to particulate issues that may pose safety and quality risks. The pharmaceutical quality of powder injections (ceftriaxone sodium) regarding particle contamination was assessed. We have selected ceftriaxone sodium because it is widely used all over the world. The powder is contained within a vial made of colourless Type II glass, which is sealed with a grey bromobutyl rubber stopper and further secured with an aluminium pilfer-proof cover. Our study primarily concentrated on particulate matter in powder injectable products. Particulate contaminants include fibres, dust, glass, and silicone. The incorporation of these components into drug products primarily occurs during the manufacturing process. The findings of our analysis indicate that the majority of the injection parameters were in accordance with the specified requirements. In some brands, we found visible particles that we further evaluated by microscopy, liquid particle counters, and FTIR, and the results showed that some kinds of fibres, glass, and silica were found (60%). Invisible 10 μm particles (limit < 6000) were also observed and determined to be of specifications in some brands (14%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.